Hairy cell leukemia and COVID-19 adaptation of treatment guidelines

Michael Grever, Leslie Andritsos, Versha Banerji, Jacqueline C. Barrientos, Seema Bhat, James S. Blachly, Timothy Call, Matthew Cross, Claire Dearden, Judit Demeter, Sasha Dietrich, Brunangelo Falini, Francesco Forconi, Douglas E. Gladstone, Alessandro Gozzetti, Sunil Iyengar, James B. Johnston, Gunnar Juliusson, Eric Kraut, Robert J. KreitmanFrancesco Lauria, Gerard Lozanski, Sameer A. Parikh, Jae Park, Aaron Polliack, Farhad Ravandi, Tadeusz Robak, Kerry A. Rogers, Alan Saven, John F. Seymour, Tamar Tadmor, Martin S. Tallman, Constantine S. Tam, Enrico Tiacci, Xavier Troussard, Clive Zent, Thorsten Zenz, Pier Luigi Zinzani, Bernhard Wörmann

Research output: Contribution to journalReview articlepeer-review

Abstract

Standard treatment options in classic HCL (cHCL) result in high response rates and near normal life expectancy. However, the disease itself and the recommended standard treatment are associated with profound and prolonged immunosuppression, increasing susceptibility to infections and the risk for a severe course of COVID-19. The Hairy Cell Leukemia Foundation (HCLF) has recently convened experts and discussed different clinical strategies for the management of these patients. The new recommendations adapt the 2017 consensus for the diagnosis and management with cHCL to the current COVID-19 pandemic. They underline the option of active surveillance in patients with low but stable blood counts, consider the use of targeted and non-immunosuppressive agents as first-line treatment for cHCL, and give recommendations on preventive measures against COVID-19.

Original languageEnglish (US)
Pages (from-to)1864-1872
Number of pages9
JournalLeukemia
Volume35
Issue number7
DOIs
StatePublished - Jul 2021

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Hairy cell leukemia and COVID-19 adaptation of treatment guidelines'. Together they form a unique fingerprint.

Cite this